mlsanityData to 7 Oct 2026

Explainable AI for Cancer Drug Response Prediction: Beyond Univariate Feature Attributions

arXiv 2607.00931 ↗First posted 1 Jul 2026cs.LGcited by 0

Not on the map. Why?

Abstract (arXiv)

Predicting cancer drug response from transcriptomic profiles is a cornerstone of precision oncology, yet the scientific value of machine learning models hinges not solely on predictive accuracy, but also on their capacity to generate reliable biological insights. Current explainability approaches in this setting are computationally costly, lack robustness, and reduce complex drug response to univariate gene importance scores, overlooking the coordinated gene activity that drives sensitivity and resistance. In this work, we present ILLUME+, a scalable post-hoc explainability framework that moves beyond single-gene assessments to capture multiple, complementary forms of explanation. Integrated into our end-to-end pipeline, ILLUME+ produces more stable gene importance scores than existing baselines, recovers established drug-gene associations and mechanisms of action, and enables AI-assisted hypothesis generation to uncover novel interaction-driven molecular signals in cancer biology.

Key facts. No citing papers in the map yet (data through 7 Oct 2026). Builds on 7 of its 75 references that are in the map. First posted on arXiv 1 Jul 2026.

Builds on

7 of 75 references.

References · 7

  1. 2017A Unified Approach to Interpreting Model Predictionscited by 6,488
  2. 2016"Why Should I Trust You?": Explaining the Predictions of Any Classifiercited by 5,040
  3. 2019Optuna: A Next-generation Hyperparameter Optimization Frameworkcited by 2,455
  4. 2016HyperNetworkscited by 1,003
  5. 2018A Survey Of Methods For Explaining Black Box Modelscited by 970
  6. 2024DRExplainer: Quantifiable Interpretability in Drug Response Prediction with Directed Graph Convolutional Networkcited by 2
  7. 2025Explanations Go Linear: Post-hoc Explainability for Tabular Data with Interpretable Meta-Encodingcited by 1

Built on by

Not cited yet.